clinical trial · NCT07564505
A Clinical Trial of Taibowei® Adalimumab Injection in the Treatment of Chinese Pediatric Patients With Moderately to Severely Active Crohn's Disease
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.·phase4·recruiting·n = 30
Children Aged 6 Years and Above With Moderate - to - Severe Active Crohn's DiseaseAdalimumab Solution for Injection
brief summary
This study is a real - world clinical research of adalimumab. The project plans to enroll 30 subjects, aiming to evaluate the incidence of serious adverse events (SAEs) within 12, 26, and 52 weeks after treatment; as well as the incidence of adverse events (AEs), adverse drug reactions (ADRs), adverse events of special interest (AESIs), and serious ADRs at 12, 26, and 52 weeks after treatment.
started
Aug 13, 2026
primary completion
Mar 1, 2029
completion
Mar 1, 2029
last updated
Sep 10, 2026
official title
Post-marketing Case Registration Study on the Safety and Efficacy of Taibowei® Adalimumab Injection for Chinese Pediatric Patients With Moderately to Severely Active Crohn's Disease
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol